1. HER-2 Protein Overexpression in Patients with Gastric and Oesophageal Adenocarcinoma at a Tertiary Care Facility in Ghana.
- Author
-
Simpong DL, Asmah RH, Krampah C, Akakpo PK, Adu P, Asante DB, Naporo S, Adjei AA, and Gyasi RK
- Subjects
- Adenocarcinoma genetics, Adolescent, Adult, Aged, Biomarkers, Tumor, Child, Child, Preschool, Esophageal Neoplasms genetics, Female, Gene Expression, Ghana, Humans, Immunohistochemistry, Infant, Infant, Newborn, Male, Middle Aged, Receptor, ErbB-2 genetics, Retrospective Studies, Stomach Neoplasms genetics, Tertiary Care Centers, Young Adult, Adenocarcinoma metabolism, Esophageal Neoplasms metabolism, Receptor, ErbB-2 metabolism, Stomach Neoplasms metabolism
- Abstract
The prognosis of gastric and oesophageal adenocarcinoma remains generally poor. However, mounting evidence suggests a positive role of human epidermal growth factor receptor-2 (HER-2) expression in the prognosis of patients with these cancers. In this work, the patterns of HER-2 protein expression were determined in patients with gastric or oesophageal adenocarcinoma. Retrospectively, we reviewed records of gastric and oesophageal biopsies received from 2008 to 2012 and their corresponding archived formalin-fixed paraffin-embedded tissue blocks selected for immunohistochemical analysis. The prevalence of gastric and oesophageal adenocarcinomas and their association with HER-2 protein overexpression were evaluated. Gastric adenocarcinoma made up 18.79% of the gastric biopsies reviewed, and majority of these cancers occurred in males. Regarding the tumour type, HER-2 overexpression was common in the intestinal subtype compared to the diffuse type. Although squamous cell carcinoma was observed to be the commonest (31%) tumour type in the oesophagus compared to adenocarcinoma (8.79%), HER-2 was overexpressed in 42.9% of oesophageal adenocarcinomas, like gastric adenocarcinoma (41.4%). There is a high prevalence of gastric and oesophageal adenocarcinoma, with significant overexpression of HER-2 in these tumours, a window of hope for the management of patients with these cancers.
- Published
- 2018
- Full Text
- View/download PDF